Jun 5 |
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
|
May 16 |
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
|
May 14 |
Q1 2024 Voyager Therapeutics Inc Earnings Call
|
May 14 |
Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript
|
May 14 |
Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
May 13 |
Voyager Therapeutics up 8% following quarterly beats
|
May 13 |
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
|
May 13 |
Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M
|
May 13 |
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
|
May 8 |
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
|